The current market requires both innovation and growth to drive the creation of new biologics. At ALLOZYNE, we demonstrate this through both of our technology platforms as well as across our pipeline to target key disease areas. Both of our platforms enable the incorporation of amino acid analogues at any position to create biologics that elicit improved efficacy, tolerability and pharmacology.